Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort - Équipe « Psychiatric disorders: neuroscience Research and clinical Research »
Article Dans Une Revue Frontiers in Pharmacology Année : 2024

Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort

Nathan Vidal (1, 2, 3) , Paul Roux (1, 2, 3) , Mathieu Urbach (1, 2, 3) , Cristobal Belmonte (1, 4, 5) , Laurent Boyer (1, 6, 7, 8) , Delphine Capdevielle (1, 4, 5, 9) , Julie Clauss-Kobayashi (1, 10, 11) , Thierry D’amato (1, 12, 13) , Romane Dassing (1, 10, 11) , Caroline Dubertret (14, 15, 1, 16) , Julien Dubreucq (1, 17, 18) , Guillaume Fond (1, 6, 7, 8) , Roxana-Mihaela Honciuc (1, 19, 20) , Sylvain Leignier (1, 17, 18) , Pierre-Michel Llorca (1, 19, 20) , Jasmina Mallet (1, 14, 15, 16) , David Misdrahi (1, 21, 22) , Baptiste Pignon (1, 23, 24) , Romain Rey (1, 12, 13) , Franck Schürhoff (1, 23, 24) , Arnaud Tessier (1, 21, 22) , Christine Passerieux (1, 2, 3) , Eric Brunet-Gouet (1, 2, 3)

Résumé

Aim: The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess anticholinergic burden and yet, there is no consensus indicating which anticholinergic burden scale is more relevant for patients with schizophrenia. We aimed to identify valid scales for estimating the risk of iatrogenic cognitive impairment in schizophrenia. Methods: We identified 27 scales in a literature review. The responses to neuropsychological tests of 839 individuals with schizophrenia or schizoaffective disorder in the FACE-SZ database were collected between 2010 and 2021. We estimated the association between objective global cognitive performance and the 27 scales, the number of psychotropic drugs, and chlorpromazine and lorazepam equivalents in bivariable regressions in a cross-sectional design. We then adjusted the bivariable models with covariates: the predictors significantly associated with cognitive performance in multiple linear regressions were considered to have good concurrent validity to assess cognitive performance. Results: Eight scales, the number of psychotropic drugs, and drug equivalents were significantly associated with cognitive impairment. The number of psychotropic drugs, the most convenient predictor to compute, was associated with worse executive function (Standardized β = -0.12, p = .004) and reasoning (Standardized β = -0.08, p = .037). Conclusion: Anticholinergic burden, the number of psychotropic drugs, and drug equivalents were weakly associated with cognition, thus suggesting that cognitive impairment in schizophrenia and schizoaffective disorder is explained by factors other than medication. The number of psychotropic drugs was the most parsimonious method to assess the risk of iatrogenic cognitive impairment.
Fichier principal
Vignette du fichier
Vidal et al 2024.pdf (1.25 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04634620 , version 1 (04-07-2024)

Licence

Identifiants

Citer

Nathan Vidal, Paul Roux, Mathieu Urbach, Cristobal Belmonte, Laurent Boyer, et al.. Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort. Frontiers in Pharmacology, 2024, 15, pp.1403093. ⟨10.3389/fphar.2024.1403093⟩. ⟨hal-04634620⟩
70 Consultations
30 Téléchargements

Altmetric

Partager

More